Aventis
16, Avenue de l'Europe
Espace Europeen de l'Entreprise
Schiltigheim
F-67300
France
Tel: 33-0-388-99-12-46
Fax: 33-0-388-99-13-75
Website: http://www.aventis.com/
Email: info@aventis.com
57 articles about Aventis
-
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
1/23/2024
Inhibrx, Inc. and Sanofi announced that the companies have entered into a definitive agreement under which Aventis Inc., a Pennsylvania corporation will acquire all the assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1 antitrypsin augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency.
-
BioSpace Movers and Shakers Oct. 29
10/29/2018
Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more. -
Nanomedicine Company Nanobiotix Elects Former Aventis Vice Chairman and CFO Patrick Langlois As its Chairman
5/12/2008
-
Aventis Pays More Than $190 Million to Settle Drug Pricing Fraud Matters
9/10/2007
-
Sanofi-Aventis Issues Strong Support for Voluntary 'Guiding Principles' on DTC Advertising
8/3/2005
-
Mechanism Proposed For Link Between RU-486 And Fatal Infections
7/27/2005
-
Sanofi-Aventis Group Release: Taxotere(R) (Docetaxel) Regimen Significantly Improves Survival In Women With Node Positive Early Stage Breast Cancer
12/10/2004
-
The Alliance For Better Bone Health Release: Actonel Provides Vertebral Fracture Risk Reduction In Women With Postmenopausal Osteoporosis At Risk For Upper GI Side Effects
10/18/2004
-
New Drugs Slow Metastatic Prostate Cancer
10/7/2004
-
Columbia University Medical Center Release: Breast Cancer Drug Taxotere(R) Extends Life Of Prostate Cancer Patients
10/7/2004
-
Sanofi Takes Top Aventis Board Slots, H1 Net Jumps
9/1/2004
-
Top Sanofi-Aventis Manager To Quit
8/25/2004
-
nAscent BioSciences Introduces PocketTips
8/23/2004
-
Paul Royalty Acquires Estorra U.S. Royalty Rights From Aventis For Up to $115 Million
8/10/2004
-
Aventis: Enoxaparin Studies Ultimately Disappointing
7/12/2004
-
Aventis Release: European Commission Approval For Arava® (Leflunomide) For Use In Adults With Psoriatic Arthritis
6/23/2004
-
Big Business vs. Big Pharma
6/18/2004
-
Aventis Insulin Withdrawals
6/17/2004
-
2004 Aventis International BioGENEius Challenge Announces Winner
6/8/2004
-
Big Pharma Could Hog Biotech's Spotlight
6/3/2004